INDEX — InDex Pharmaceuticals Holding AB Income Statement
0.000.00%
Last trade - 00:00
- SEK175.79m
- -SEK116.18m
- SEK97.51m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.088 | 0.035 | 0 | 0 | 97.5 |
Cost of Revenue | |||||
Gross Profit | -74 | -47 | -102 | -137 | -79.9 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 87.8 | 57.4 | 103 | 103 | 205 |
Operating Profit | -87.7 | -57.3 | -103 | -103 | -107 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -87.8 | -57.4 | -103 | -100 | -95.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -87.8 | -57.4 | -103 | -100 | -95.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -87.8 | -57.4 | -103 | -100 | -95.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -87.8 | -57.4 | -103 | -100 | -95.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.446 | -0.091 | -0.213 | -0.188 | -0.179 |
Dividends per Share |